AR095885A1 - Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 - Google Patents
Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2Info
- Publication number
- AR095885A1 AR095885A1 ARP140101626A ARP140101626A AR095885A1 AR 095885 A1 AR095885 A1 AR 095885A1 AR P140101626 A ARP140101626 A AR P140101626A AR P140101626 A ARP140101626 A AR P140101626A AR 095885 A1 AR095885 A1 AR 095885A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- carbonitrile
- pyrrolo
- pyridine
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 title abstract 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000005262 alkoxyamine group Chemical group 0.000 abstract 2
- 150000003973 alkyl amines Chemical class 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- VYEFDAQRXKQMPZ-UHFFFAOYSA-N 4-(2,4-dimethylphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(C)=CC=C1C1=CC=NC2=C1C(C#N)=CN2 VYEFDAQRXKQMPZ-UHFFFAOYSA-N 0.000 abstract 1
- NSJGIUMXLVXGPU-UHFFFAOYSA-N 4-(3-hydroxyphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound OC1=CC=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=C1 NSJGIUMXLVXGPU-UHFFFAOYSA-N 0.000 abstract 1
- WRQMDDJZRIRGLV-UHFFFAOYSA-N 4-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound N#Cc1c[nH]c2nccc(-c3ccccc3)c12 WRQMDDJZRIRGLV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Los compuestos se consideran útiles para el tratamiento de enfermedades asociadas con LRRK2, tales como la demencia de cuerpos de Lewy, la enfermedad de Parkinson o el cáncer. Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ representa H o un grupo NHR²; R² representa H o un anillo heteroaromático de 5 ó 6 miembros con 1 ó 2 N, cuyo anillo heteroaromático está opcionalmente sustituido con 1 ó 2 grupos seleccionados cada uno independientemente del grupo que comprende CF₃, halógeno, alquilo C₁₋₃, alcoxi C₁₋₃, alquilamina C₁₋₃ o alcoxiamina C₁₋₃; R³ representa un anillo aromático de 5 ó 6 miembros o un anillo heteroaromático de 5 ó 6 miembros con 1 ó 2 heteroátomos(s) seleccionados de S o N, cuyo anillo aromático o anillo heteroaromático está opcionalmente sustituido con H, OH, 1 ó 2 alquilo C₁₋₃, 1 ó 2 alcoxi C₁₋₃ o un trifluorometilo; L está ausente o representa (CH₂)ₙ, n = 1 ó 2; R⁴ representa H, NH₂ o un anillo heterocíclico de 5 ó 6 miembros con 1 ó 2 heteroátomos(s) seleccionados de N u O, cuyo anillo heterocíclico está opcionalmente sustituido con 1 ó 2 alquilo C₁₋₃, 1 ó 2 alcoxi C₂₋₃, 1 ó 2 alquilamina C₁₋₃ o 1 ó 2 alcoxiamina C₂₋₃; o una sal farmacéuticamente aceptable del mismo, con la condición de que el compuesto no se selecciona de 4-fenil-1H-pirrolo[2,3-b]piridina-3-carbonitrilo, 4-(3-hidroxifenil)-1H-pirrolo[2,3-b]piridina-3-carbonitrilo o 4-(2,4-dimetilfenil)-1H-pirrolo[2,3-b]piridina-3-carbonitrilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300231 | 2013-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095885A1 true AR095885A1 (es) | 2015-11-18 |
Family
ID=59093654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101626A AR095885A1 (es) | 2013-04-18 | 2014-04-16 | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9499542B2 (es) |
| EP (1) | EP2986608B1 (es) |
| JP (1) | JP6461097B2 (es) |
| CN (1) | CN105263930B (es) |
| AR (1) | AR095885A1 (es) |
| ES (1) | ES2642204T3 (es) |
| HK (1) | HK1222387A1 (es) |
| TW (1) | TW201533043A (es) |
| WO (1) | WO2014170248A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| WO2017106771A1 (en) | 2015-12-16 | 2017-06-22 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| KR20230107407A (ko) | 2016-06-16 | 2023-07-14 | 데날리 테라퓨틱스 인크. | 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서피리미딘-2-일아미노-1h-피라졸 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) * | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| KR101923852B1 (ko) * | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| AU2018239798B2 (en) * | 2017-03-23 | 2020-08-27 | Daegu Gyeongbuk Institute Of Science And Technology | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
| KR20190043437A (ko) * | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR20200085779A (ko) * | 2017-12-05 | 2020-07-15 | 주식회사 오스코텍 | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 |
| US11634416B2 (en) | 2017-12-14 | 2023-04-25 | H. Lundbeck A/S | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN111511742B (zh) | 2017-12-20 | 2023-10-27 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| WO2020023393A1 (en) * | 2018-07-23 | 2020-01-30 | Bioblocks, Inc. | Kinase antagonists and methods for making and using them |
| KR101990739B1 (ko) * | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101992059B1 (ko) * | 2018-08-23 | 2019-06-21 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR102133595B1 (ko) * | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| WO2022089497A1 (zh) * | 2020-10-29 | 2022-05-05 | 苏州亚宝药物研发有限公司 | 取代的二芳基胺化合物及其药物组合物、制备方法和用途 |
| CN112852954A (zh) * | 2021-03-16 | 2021-05-28 | 江苏贝格尔生物医药有限公司 | 一种检测lrrk2基因1628多态性的引物和探针及试剂盒 |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| WO2023239727A1 (en) * | 2022-06-06 | 2023-12-14 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Lats inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1628975A2 (en) * | 2003-05-16 | 2006-03-01 | Eisai Co., Ltd. | Jnk inhibitors |
| JP2009521504A (ja) | 2005-12-22 | 2009-06-04 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性阻害剤 |
| EP1979353A2 (en) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| JP2009525350A (ja) * | 2006-02-01 | 2009-07-09 | スミスクライン ビーチャム コーポレーション | Ｒａｆキナーゼ阻害薬として有用なピロロ［２，３，ｂ］ピリジン誘導体 |
| GB0617161D0 (en) | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
| WO2008110508A1 (en) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
| MX2009009936A (es) * | 2007-03-20 | 2010-02-11 | Curis Inc | Amino piridina fusionada como inhibidores de hsp90. |
| CN102428084B (zh) * | 2009-03-19 | 2016-05-18 | 医疗技术研究局 | 化合物 |
| GB201008134D0 (en) * | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| GB201015949D0 (en) * | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| JP5961683B2 (ja) | 2011-04-05 | 2016-08-02 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
-
2014
- 2014-04-08 TW TW103112818A patent/TW201533043A/zh unknown
- 2014-04-14 ES ES14720062.0T patent/ES2642204T3/es active Active
- 2014-04-14 JP JP2016508109A patent/JP6461097B2/ja active Active
- 2014-04-14 CN CN201480021665.9A patent/CN105263930B/zh active Active
- 2014-04-14 EP EP14720062.0A patent/EP2986608B1/en active Active
- 2014-04-14 WO PCT/EP2014/057482 patent/WO2014170248A1/en active Application Filing
- 2014-04-14 US US14/777,805 patent/US9499542B2/en active Active
- 2014-04-16 AR ARP140101626A patent/AR095885A1/es unknown
- 2014-04-17 US US14/255,317 patent/US20140315901A1/en not_active Abandoned
-
2016
- 2016-08-24 HK HK16110103.5A patent/HK1222387A1/zh unknown
- 2016-10-07 US US15/288,255 patent/US9675594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105263930A (zh) | 2016-01-20 |
| US20140315901A1 (en) | 2014-10-23 |
| JP2016516791A (ja) | 2016-06-09 |
| EP2986608A1 (en) | 2016-02-24 |
| CN105263930B (zh) | 2017-06-09 |
| US20170020850A1 (en) | 2017-01-26 |
| TW201533043A (zh) | 2015-09-01 |
| EP2986608B1 (en) | 2017-08-23 |
| ES2642204T3 (es) | 2017-11-15 |
| US9675594B2 (en) | 2017-06-13 |
| US20160102089A1 (en) | 2016-04-14 |
| US9499542B2 (en) | 2016-11-22 |
| WO2014170248A1 (en) | 2014-10-23 |
| JP6461097B2 (ja) | 2019-01-30 |
| HK1222387A1 (zh) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| TR201904658T4 (tr) | Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları. | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| MA40170A (fr) | Dérivés hétérocycliques de morphinan et leur utilisation | |
| AR101456A1 (es) | Inhibidores de cinasa c de proteína y métodos para usarse | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| AR103412A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR097739A1 (es) | Imidazo[1,2-a]piridina-7-aminas | |
| UY36124A (es) | Derivados de carboxamida | |
| UY36123A (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |